Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study

Abstract Introduction Pyoderma gangrenosum (PG) is a rare, autoinflammatory skin disorder characterized by painful ulcers, with scarce treatment options. Adalimumab is a recently approved tumor necrosis factor-alpha inhibitor for PG, for which real-world data remain limited. This study evaluated the...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Toshiyuki Yamamoto, Hideaki Tanizaki, Kenshi Yamasaki, Naoko Matsubara, Masahiko Nakayama, Eri Iwashita, Keiichi Yamanaka
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Adis, Springer Healthcare 2026-05-01
Sarja:	Dermatology and Therapy
Aiheet:	Adalimumab Humira Postmarketing surveillance Pyoderma gangrenosum Real-world evidence Safety
Linkit:	https://doi.org/10.1007/s13555-026-01772-4
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!